Hiroki Hidejima
Directeur/Bestuurslid bij METAREAL CORPORATION
Vermogen: 1 M $ op 30-04-2024
Actieve functies van Hiroki Hidejima
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
METAREAL CORPORATION | Directeur/Bestuurslid | 01-04-2004 | - |
J & I YK | Directeur/Bestuurslid | 01-02-2004 | - |
YES-fm KK | Comptroller/Controller/Auditor | 01-03-2005 | - |
C.H.C. SYSTEM Co., Ltd. | Directeur/Bestuurslid | 01-05-2005 | - |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Directeur/Bestuurslid | 01-07-2010 | - |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Directeur/Bestuurslid | 01-06-2014 | - |
THANN Natural KK | Directeur/Bestuurslid | 01-06-2012 | - |
Development Association For Youthleaders | Directeur/Bestuurslid | 01-03-2004 | - |
Loopbaan van Hiroki Hidejima
Opleiding van Hiroki Hidejima
Kobe University Graduate School of Business Administration | Undergraduate Degree |
Statistieken
Internationaal
Japan | 9 |
Duitsland | 2 |
Operationeel
Director/Board Member | 7 |
Undergraduate Degree | 1 |
Comptroller/Controller/Auditor | 1 |
Sectoraal
Technology Services | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
METAREAL CORPORATION | Technology Services |
Bedrijven in privébezit | 7 |
---|---|
J & I YK | |
YES-fm KK | |
C.H.C. SYSTEM Co., Ltd. | |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Commercial Services |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Health Technology |
THANN Natural KK | |
Development Association For Youthleaders |
- Beurs
- Insiders
- Hiroki Hidejima
- Ervaring